RxTrials Institute Drug Pipeline Alert

Celldex Therapeutics’ Phase I clinical trials of its cancer vaccine candidate, CDX-1307, combined with a protein, GM-CSF, showed encouraging results.

The open-label, dose-escalating studies evaluated the safety and immunogenicity of the drug alone and in combination with GM-CSF in patients with incurable breast, bladder, pancreatic or colorectal cancer. The drug was well tolerated, providing a basis for further testing in combination with more potent adjuvants, Celldex said.

The company expects more data in the first half of 2009.